8-K: CVRx Q3 2025 Revenue Up 10%, Raises Full-Year Guidance

CVRx, Inc. reported a 10% increase in third-quarter 2025 total revenue to $14.7 million and updated its full-year guidance with higher revenue and gross margin expectations.

Summary

• Total revenue for the third quarter of 2025 was $14.7 million, representing a 10% increase compared to the prior year quarter.
• U.S. revenue for Q3 2025 reached $13.5 million, also a 10% increase year-over-year, driven by new sales territories, accounts, and increased Barostim awareness.
• Active implanting centers in the U.S. grew to 250 as of September 30, 2025, marking a 20% increase since September 30, 2024.
• Gross profit for Q3 2025 was $12.8 million, a 15% increase, with gross margin improving to 87% from 83% in Q3 2024 due to higher average selling prices and manufacturing efficiencies.
• Net loss for the quarter was $12.9 million, or $0.49 per share, an improvement from a net loss of $13.1 million, or $0.57 per share, in the prior year quarter.
• Cash and cash equivalents stood at $85.1 million as of September 30, 2025.
• The company updated its full-year 2025 guidance, now expecting total revenue between $55.6 million and $56.6 million, gross margin between 85% and 86%, and operating expenses between $98.0 million and $99.0 million.
• For the fourth quarter of 2025, total revenue is projected to be between $15.0 million and $16.0 million.

Sentiment

Score: 7

Explanation: The company delivered solid revenue growth, significant gross margin expansion, and an improved net loss per share. The positive regulatory development with CMS for 2026 CPT codes is a strong future catalyst. While still unprofitable and increasing operating expenses, the overall trajectory and management's confidence reflected in updated guidance are positive, indicating a favorable outlook despite ongoing losses.

Positives

• Total revenue increased 10% year-over-year to $14.7 million in Q3 2025, demonstrating solid growth.
• U.S. revenue also increased 10% year-over-year to $13.5 million, driven by successful commercial strategy execution, including expansion into new sales territories and accounts.
• Active implanting centers in the U.S. grew to 250, a 20% increase since September 30, 2024, indicating expanding customer adoption.
• Gross profit increased 15% to $12.8 million, and gross margin significantly improved to 87% in Q3 2025 from 83% in Q3 2024, attributed to higher average selling prices and enhanced manufacturing efficiencies.
• Net loss per share improved to $0.49 from $0.57 in the prior year quarter, despite an increase in weighted average shares outstanding.
• CMS published a final rule assigning favorable physician fee payment levels for Category I CPT codes set to take effect in 2026, which is expected to improve patient access and remove key adoption barriers for Barostim.
• The company raised its full-year 2025 gross margin guidance to 85%-86% (from 83%-84%) and narrowed its full-year revenue guidance, reflecting confidence in continued operational performance.

Negatives

• The company reported a net loss of $12.9 million for Q3 2025, indicating continued unprofitability.
• Research and development expenses increased 26% to $3.1 million, primarily due to higher compensation and consulting expenses.
• Selling, general and administrative expenses increased 1% to $21.9 million, driven by increases in consulting, travel, and non-cash stock-based compensation.
• Interest expense increased by $0.5 million due to higher levels of borrowings under the term loan agreement.
• European revenue units decreased to 50 in Q3 2025 compared to 56 in the prior year period, despite a 12% increase in European revenue.
• Cash and cash equivalents decreased to $85.1 million as of September 30, 2025, from $105.9 million at December 31, 2024.
• Net cash used in operating and investing activities was $10.0 million for Q3 2025.
• Full-year 2025 operating expenses guidance was increased to between $98.0 million and $99.0 million from prior guidance of $96.0 million to $98.0 million.

Risks

• The company has a history of significant losses, which are expected to continue.
• There is limited history operating as a commercial company and dependence on a single product, Barostim.
• The company has limited commercial sales experience marketing and selling Barostim.
• The ability to continue demonstrating to physicians and patients the merits of Barostim is crucial for adoption.
• Any failure by third-party payors to provide adequate coverage and reimbursement for Barostim could hinder growth.
• Competitors' success in developing and marketing products that are safer, more effective, less costly, easier to use, or otherwise more attractive than Barostim poses a threat.
• Any failure to receive access to hospitals could limit market penetration.
• Dependence upon third-party manufacturers and suppliers, and in some cases a limited number of suppliers, introduces supply chain risks.
• A pandemic, epidemic, or outbreak of an infectious disease in the U.S. or worldwide could impact operations.
• Product liability claims could result in significant financial and reputational damage.
• Future lawsuits to protect or enforce intellectual property could be expensive, time-consuming, and ultimately unsuccessful.
• Any failure to retain key executives or recruit and hire new employees could impact performance.
• Impacts on adoption and regulatory approvals resulting from additional long-term clinical data about the product are possible.

Future Outlook

For the full year 2025, CVRx updated its guidance, now expecting total revenue between $55.6 million and $56.6 million, gross margin between 85% and 86%, and operating expenses between $98.0 million and $99.0 million. For the fourth quarter of 2025, the company anticipates total revenue between $15.0 million and $16.0 million. The company also highlighted the positive impact of CMS finalizing favorable physician fee payment levels for Category I CPT codes, which are set to take effect in 2026, improving patient access and removing adoption barriers.

Management Comments

• "We're pleased with the solid progress we made in the third quarter as we continue to execute and build momentum across the organization."
• "Our revised commercial strategy continues to show positive results. The development of our territories is progressing nicely as our newest reps are becoming increasingly more productive, resulting in both higher Barostim implant volumes and the expansion of our customer base."
• "We're also pleased that CMS finalized our transition to Category I CPT codes, both improving patient access and removing key adoption barriers."
• "Our focus remains on positively impacting the lives of patients who suffer from heart failure, and we are well positioned to drive deeper adoption going forward."

Industry Context

CVRx operates in the specialized medical device sector, focusing on neuromodulation solutions for cardiovascular diseases, particularly heart failure. The company's Barostim therapy, which is FDA-approved and CE Mark certified, addresses a significant unmet medical need. The recent finalization by CMS of favorable physician fee payment levels for Category I CPT codes, effective in 2026, represents a crucial regulatory development. This move is expected to significantly enhance patient access and accelerate the adoption of neuromodulation devices like Barostim within the U.S. healthcare system, positioning CVRx favorably within its niche.

Stakeholder Impact

• Shareholders: Positive impact from revenue growth, improved gross margin, reduced net loss per share, and a favorable future outlook supported by updated guidance and CMS CPT code finalization.
• Patients: Anticipated improved access to Barostim therapy starting in 2026 due to favorable CMS physician fee payment levels and the removal of adoption barriers.
• Employees: Continued growth and expansion of sales territories (three new U.S. territories added) suggest stable to growing employment opportunities, particularly for sales representatives.
• Customers (Implanting Centers): Growth in active implanting centers (250 in U.S.) indicates increasing adoption and utilization of Barostim, potentially leading to stronger partnerships and support.

Next Steps

• Host a conference call on November 5, 2025, at 4:30 p.m. Eastern Time to discuss the Q3 2025 financial and operating results.
• Continue to execute the revised commercial strategy to drive Barostim implant volumes and expand the customer base.
• Focus on positively impacting the lives of patients suffering from heart failure and driving deeper adoption of Barostim therapy.
• Prepare for the transition to Category I CPT codes in 2026, which are expected to improve patient access and remove adoption barriers.

Key Dates

Recommendation

CVRx demonstrates promising growth in revenue and gross margin, coupled with a significant regulatory tailwind from CMS for 2026, which should enhance market access. The improvement in net loss per share is also a positive indicator. However, the company remains unprofitable, with increasing R&D and SG&A expenses, and a decrease in cash reserves. While the long-term outlook appears favorable due to market expansion and regulatory support, the current unprofitability and cash burn suggest a 'hold' recommendation until there's a clearer path to sustained profitability or positive cash flow. The stock has potential, but current financial metrics warrant caution.

Keywords

CVRx, CVRX, Barostim, neuromodulation, heart failure, medical device, cardiovascular disease, Q3 2025, financial results, revenue, gross margin, CMS, CPT codes